About OriCiro Genomics
OriCiro Genomics is a company based in Tokyo (Japan) founded in 2018 was acquired by Moderna in January 2023. OriCiro Genomics has raised $10.87 million across 4 funding rounds from investors including Moderna, Asahi Kasei and UT-EC Japan. OriCiro Genomics operates in a competitive market with competitors including Amyris, Syngenta, AskBio, Ginkgo Bioworks and Twist Bioscience, among others.
- Headquarter Tokyo, Japan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of OriCiro Genomics
Unlock access to complete
Funding Insights of OriCiro Genomics
OriCiro Genomics has successfully raised a total of $10.87M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OriCiro Genomics
OriCiro Genomics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Moderna, Asahi Kasei and UT-EC Japan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and Early stage VC firm investing in Japan
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for OriCiro Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OriCiro Genomics
Investment portfolio details for OriCiro Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OriCiro Genomics
Detailed financials for OriCiro Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oriciro Genomics Comparisons
Peer comparison for OriCiro Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OriCiro Genomics
OriCiro Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, AskBio, Ginkgo Bioworks and Twist Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Gene editing-based cultured ingredients are provided for agriculture.
|
|
| Locked | Locked | Locked |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
Detailed competitors of OriCiro Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oriciro Genomics
Complete news archive for OriCiro Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OriCiro Genomics
OriCiro Genomics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
OriCiro Genomics is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
OriCiro Genomics is a funded company, having raised a total of $10.87M across 4 funding rounds to date.
OriCiro Genomics was established in 2018 in Tokyo, Japan, within the biotechnology sector. Focus is placed on developing technologies for DNA synthesis and amplification. The OriCiro Cell-Free Cloning System is provided, consisting of the OriCiro Assembly Kit and OriCiro Amp Kit. Cell-free assembly and amplification of circular DNA molecules are facilitated through this system, supporting genomic research and applications. Operations are centered in Japan, with a domain at oriciro.com.
OriCiro Genomics's top competitors include Syngenta, Synthego and Nuclera Nucleics.
OriCiro Genomics has 5 investors. Key investors include Moderna, Asahi Kasei, UT-EC Japan, ITV, and JFC.